Getting your player ready...
Boulder-based Array BioPharma Inc. shares fell the most in 21 months in Nasdaq trading after the company said one of its lead drug candidates, a rheumatoid arthritis pill, failed in a trial.
Array fell 23 percent, or 88 cents, to close Friday at $2.90.
The pill, ARRY-162, didn’t ease symptoms of the inflammatory joint disease more than a placebo, Array said Thursday in a statement released after the stock market had closed.
